Results of the murine forced swim test and spontaneous locomotor activity tests for ivacaftor, fluoxetine and ketamine. a) Schematic diagram depicting.

Slides:



Advertisements
Similar presentations
Echocardiography view
Advertisements

Results of the AweScoreCF questionnaire completed by 23 adult cystic fibrosis (CF) patients 1 month before and 3 months after initiating ivacaftor–lumacaftor.
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
Comparison of the characteristics at first enrolment for United Network for Organ Sharing (UNOS) patients (n=8315) and virtual patients (n=2 048 784).
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Survival without tracheostomy
Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);
The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.
Molecular docking models of a) ivacaftor bound to the 5-hydroxytryptamine (5-HT; serotonin) 5-HT2C receptor and b) ivacaftorcarboxylate (iva-M6) bound.
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.
A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.
Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.
Bland–Altman plot of slopes of measurement 1 versus 2
Bland–Altman comparison of lung clearance index (LCI) from multiple breath wash-out following open and modified closed circuit wash-in for both healthy.
A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.
Cluster diagram for four patient pairs with genotyped strains sharing the same sequence typing (ST). Cluster diagram for four patient pairs with genotyped.
Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.
Electromyographic responses of the diaphagm to cervical magnetic stimulations (CMS), recorded with the intramuscular electrodes implanted for diaphragm.
Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.
Venn diagram showing the overlap between the various chronic obstructive pulmonary disease (COPD) diagnoses: self-reported physician-diagnosed, fixed ratio.
Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.
Forest plot displaying the effect estimates comparing azithromycin and placebo treatment in subgroups defined by above (>0.39 ng·mL−1) or below (
Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.
A white elephant or the elephant in the room
Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.
a) Secondary binding data for ivacaftor
Comparison of absolute counts for a, b) white blood cells (WBC), c, d) neutrophils, e, f) monocytes, and g, h) eosinophils for 100 patients with lymphangioleiomyomatosis.
A) The flexible 1.9 mm diameter and 900 mm length cryoprobe, b) connected to the cryotherapy equipment. c) Marks on the distal area of the probe (1 cm.
Most frequent words and phrases based on user comments about the registry. Most frequent words and phrases based on user comments about the registry. Word.
Portions of two representative reports, a, c and e) one during noninvasive ventilation through a helmet and b, d and f) the other through mask. Portions.
Forest plot of the effect of “add-on” therapies on 6-min walking distance change (in metres). Forest plot of the effect of “add-on” therapies on 6-min.
Concentration of inflammatory cytokines in epithelial lining fluid (ELF) were plotted for the normal control, smoker normal forced oscillation technique.
Pressure increase delivered by the tested automatic continuous positive airway pressure devices during the first 10 min of the bench test. Pressure increase.
Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.
a) Mortality per time point (p<0
Distribution of the differences in smallest worthwhile effects (SWEs) of land-based and water-based pulmonary rehabilitation on 6-min walk distance (in.
Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.
Venn diagram showing the overlap between the various spirometric definitions of airway obstruction and respiratory symptoms. **: p
Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.
A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.
Patients' and partners' experience of anxiety in the Netherlands (NL) and Germany (GE), based on the Generalised Anxiety Disorder-single item questionnaire.
The regression lines between the asynchrony index (AI) and the double true index (DTI) shown for overall data, and for mask and helmet separately. The.
Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.
Relationship between bronchodilator response of physiological parameters and concentration of interleukin (IL)-8 in epithelial lining fluid (ELF). Relationship.
Receiver operating characteristic (ROC) curves (area under the curve (AUC) (95% CI)) for FACED (forced expiratory volume in 1 s, age, chronic colonisation.
Concordance of review article recommendations with contemporary guidelines. Concordance of review article recommendations with contemporary guidelines.
Α1-Antitrypsin (AAT) therapy considerations: a) practical difficulties with AAT infusions; b) concerns regarding AAT doses >60 mg·kg−1 per week. α1-Antitrypsin.
Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).
Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.
Diagram of rebreathe apparatus.
Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.
Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.
Physician perspectives on self-administration of i. v. α1-antitrypsin
Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.
Post-operative a) neutrophil counts, but not b) lymphocyte or c) platelet counts, were higher in current smokers than ex-smokers. #: time-points were statistically.
A) Forced expiratory volume in 1 s (FEV1) and b) 6-min walk test (6MWT) distance by bronchiectasis in any lobe/vascular pruning in the lower lobes groups.
Bland–Altman comparison of functional residual capacity (FRC) measured from multiple breath wash-out following open and modified closed circuit wash-in.
A) Schematic diagram of the function principles of a noninvasive mechanical ventilator. b) Diagram of conventional noninvasive mechanical ventilators.
Composition of the most common clusters at the a) onset of the first acute respiratory tract infection (swab A) and b) 3 weeks later (swab B) illustrated.
Absolute change in forced expiratory volume in 1 s (FEV1) % pred over time in clinical trials with a) ivacaftor (IVA) in patients with at least one G551D.
Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to the presence of acute respiratory failure (ARF) and.
Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)
Results of the murine forced swim test and spontaneous locomotor activity tests for ivacaftor, fluoxetine and ketamine. a) Schematic diagram depicting.
Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.
Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,
Study design for ECLIPSE (VX-659 triple combination) and AURORA (VX-445 triple combination) phase 3 studies. Study design for ECLIPSE (VX-659 triple combination)
Presentation transcript:

Results of the murine forced swim test and spontaneous locomotor activity tests for ivacaftor, fluoxetine and ketamine. a) Schematic diagram depicting the forced swim test. b) Effect of ivacaftor treatment (40 mg·kg−1 i.p. for 21 days) on swimming and climb... Results of the murine forced swim test and spontaneous locomotor activity tests for ivacaftor, fluoxetine and ketamine. a) Schematic diagram depicting the forced swim test. b) Effect of ivacaftor treatment (40 mg·kg−1i.p. for 21 days) on swimming and climbing in the forced swim test (n=10). Fluoxetine (10.2 mg·kg−1i.p. for 21 days) and ketamine (10 mg·kg−1s.c.) were used as the comparators. c) Effect of ivacaftor, fluoxetine and ketamine on immobility in the forced swim test (n=10). *: p<0.05. d) Effect of ivacaftor and fluoxetine on spontaneous locomotor activity in the open field test measuring the distance (cm) travelled for 10 min (n=10). e) Effect of ivacaftor, fluoxetine and ketamine on spontaneous locomotor activity in the open field test measuring the number of touches for 10 min (n=10). Elena K. Schneider et al. ERJ Open Res 2018;4:00127-2017 ©2018 by European Respiratory Society